3 July 2022 in Advanced Drug Delivery Reviews
29 September 2017 in Circulation Research
Unawareness or neglecting that extracellular vesicles (EVs) and lipoproteins coisolate when using a traditional 1-step physical-based purification method to isolate one of these entities from plasma is a major issue. This issue ultimately leads to wrong conclusions about the composition and biological functions of these bionanoparticles. Here, I highlight the biophysical similarities between EVs and lipoproteins and their different abundances in plasma that result in the unintentional coisolation of these 2 different entities. Concerns related to nonq uantitative measures of mass spectrometry (MS) and quantitative polymerase chain reaction (qPCR)–based data and the dynamics of certain apolipoproteins are also stressed because these facets, like the coisolation issue, may challenge our understanding of what we are actually looking at when we are studying apparently purified EV or lipoprotein samples. EVs and lipoproteins are biological nanoparticles that can be found in the circulatory system. Among the many biological functions, including cardiovascular, of EVs and lipoproteins is their proposed ability to deliver biological cargo (beyond lipids in the case of lipoproteins) from one cell to a distant recipient cell. Thus, these biological vehicles may be key mediators of intercellular communication. As such, EVs and lipoproteins have the potential to serve as disease biomarkers and to deliver therapeutic compounds to specific biological targets. However, a proper isolation and characterization of EVs and lipoproteins is crucial and often a prerequisite for being able to investigate the biological properties of these specific entities and to exploit and realize their full clinical potential. EVs are cell-derived nanoscale vesicles that carry nucleic acids, proteins, and other biomolecular compounds from their cells of origin. EVs constitute a heterogeneous population of vesicles secreted via different mechanisms—to all kinds of body fluids. The young EV research field has received increased attention during the last decade. EV classification efforts are impeded by the …
1 January 2019 in Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
Circulating biomarkers have a great potential in diagnosing cancer diseases at early stages, where curative treatment is a realistic possibility. In the recent years, using extracellular vesicles (EVs) derived from blood as biomarkers has gained widespread popularity, mainly because they are thought to be easy to isolate and carry a vast variety of biological cargos that can be analyzed for biomarker purposes. However, our current knowledge on the plasma EV concentration in normophysiological states is sparse. Here, we provide the very first mean estimate of the plasma EV concentration based on values obtained from a thorough literature review. The different estimates obtained from the literature are correlated to the isolation techniques used to obtain them, illustrating how some methodologies may over- or underestimate the plasma EV concentration. We also show that the estimated plasma EV concentration (approximately 1010 EVs per mL) defines EVs as a minority population compared to other colloidal particles of the systemic circulation, namely the lipoproteins, which are known contaminants in EV isolates and carry biomarker molecules themselves. Lastly, we introduce the possibility of regarding EVs and lipoproteins as a continuum of lipid-containing particles to which biomarker molecules can be associated. Using such a holistic approach, increased strength of plasma-derived cancer biomarkers may soon be revealed.
20 February 2019 in Journal of Extracellular Vesicles
Post‐staining of extracellular vesicles (EVs) with lipid‐anchored fluorophores (LAFs) such as PKH67 is a widely used strategy for studying EVs but it is associated with several pitfalls. The pitfalls discussed in this commentary are related to LAF labelling of non‐EV species due to (1) lipoprotein contamination in EV samples, (2) desorption of the LAF reporters from vesicles into proteins and lipoproteins in blood and serum, and (3) the capability of the amphiphilic LAF compounds to form EV‐like particles. Awareness of these challenges and developing solutions to overcome these are important to ensure that we make relevant interpretations when using LAFs to track EVs.
1 July 2019 in Journal of Controlled Release
9 September 2010 in Journal of the American Chemical Society